{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:32:55Z","timestamp":1790181175349,"version":"4.1.0"},"reference-count":68,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Uterine mesenchymal tumors (UMTs) are the second most common type of tumors within the uterus corpus after endometrial carcinomas. Among the UMTs, smooth muscle neoplasms are the most common subtype, followed by endometrial stromal sarcoma (ESS). ESSs are uncommon malignancies characterized by molecular heterogeneity and an aggressive behavior. Their management poses significant challenges, particularly for high-grade subtypes. Surgery is the primary intervention for localized disease, while the role of adjuvant therapies, including radiation and chemotherapy, must be better investigated. Hormonal therapy has shown efficacy in low-grade cases but limited success in high-grade tumors. Recent advancements in molecular profiling have revealed potential targets, offering promise for personalized treatments. However, novel therapeutic strategies are urgently needed to improve patient outcomes, particularly for advanced and recurrent disease. This review offers a perspective on the possible novel therapeutic approaches based on the most recent molecular analyses performed on endometrial stromal sarcomas.<\/jats:p>","DOI":"10.3390\/biom15020265","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T11:54:06Z","timestamp":1739274846000},"page":"265","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Molecular Insights in Endometrial Stromal Sarcomas: Exploring New Targets for Novel Therapeutic Approaches"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0809-2512","authenticated-orcid":false,"given":"Alice","family":"Costa","sequence":"first","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2732-0747","authenticated-orcid":false,"given":"Annalisa","family":"Astolfi","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"},{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Gozzellino","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2103-1960","authenticated-orcid":false,"given":"Margherita","family":"Nannini","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna, 40138 Bologna, Italy"},{"name":"Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1506-1829","authenticated-orcid":false,"given":"Gianandrea","family":"Pasquinelli","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna, 40138 Bologna, Italy"},{"name":"Division of Pathology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Abbondanza","family":"Pantaleo","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna, 40138 Bologna, Italy"},{"name":"Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1200\/EDBK_350955","article-title":"Uterine Sarcomas: How to Navigate an Ever-Growing List of Subtypes","volume":"42","author":"Roy","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. B"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Alodaini, A.A. (2024). Uterine Mesenchymal Tumors: Updates on Pathology, Molecular Landscape, and Therapeutics. Medicina, 60.","DOI":"10.3390\/medicina60071085"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Dall, G.V., Hamilton, A., Ratnayake, G., Scott, C., and Barker, H. (2022). Interrogating the Genomic Landscape of Uterine Leiomyosarcoma: A Potential for Patient Benefit. Cancers, 14.","DOI":"10.3390\/cancers14061561"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Yang, Q., Madueke-Laveaux, O.S., Cun, H., Wlodarczyk, M., Garcia, N., and CC, K. (2024). A-HA Comprehensive Review of Uterine Leiomyosarcoma: Pathogenesis, Diagnosis, Prognosis, and Targeted Therapy. Cells, 13.","DOI":"10.3390\/cells13131106"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4103\/jcrt.jcrt_741_22","article-title":"Endometrial Stromal Tumors: A Clinico-histomorphological Spectrum of Endometrial Stromal Tumors with Review of Literature","volume":"20","author":"Verma","year":"2023","journal-title":"J. Cancer Res. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ygyno.2023.02.009","article-title":"Endometrial Stromal Tumors of the Uterus: Epidemiology, Pathological and Biological Features, Treatment Options and Clinical Outcomes","volume":"171","author":"Gadducci","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Akaev, I., Yeoh, C.C., and Rahimi, S. (2021). Update on Endometrial Stromal Tumours of the Uterus. Diagnostics, 11.","DOI":"10.3390\/diagnostics11030429"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"17588359231157645","DOI":"10.1177\/17588359231157645","article-title":"Uterine Sarcomas: Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up, by Spanish Group for Research on Sarcomas (GEIS)","volume":"15","author":"Ortega","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","article-title":"Soft Tissue and Visceral Sarcomas: ESMO\u2013EURACAN\u2013GENTURIS Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"32","author":"Gronchi","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_10","unstructured":"World Health Organization (2020). WHO Classification of Tumours Editorial Board. Female Genital Tumours, International Agency for Research on Cancer. Available online: https:\/\/tumourclassification.iarc.who.int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1007\/s12094-020-02512-6","article-title":"Survival Outcomes and Prognostic Factors of Endometrial Stromal Sarcoma and Undifferentiated Uterine Sarcoma","volume":"23","author":"Cabrera","year":"2021","journal-title":"Clin. Transl. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/cam4.2044","article-title":"Hormonal Therapy in Uterine Sarcomas","volume":"8","author":"Zang","year":"2019","journal-title":"Cancer Med."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Borella, F., Bertero, L., Cassoni, P., Piovano, E., Gallio, N., Biglia, N., and Benedetto, C. (2022). Low-Grade Uterine Endometrial Stromal Sarcoma: Prognostic Analysis of Clinico-Pathological Characteristics, Surgical Management, and Adjuvant Treatments. Experience From Two Referral Centers. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.883344"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"101589","DOI":"10.1016\/j.suronc.2021.101589","article-title":"Role of Lymphadenectomy for Apparent Early Stage Uterine Sarcoma; a Comprehensive Analysis of the National Cancer Database","volume":"38","author":"Nasioudis","year":"2021","journal-title":"Surg. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"101248","DOI":"10.1016\/j.gore.2023.101248","article-title":"High-Grade Endometrial Stromal Sarcoma with YWHAE-NUTM2B Fusion Gene Abnormality Identified after 10 Years of Recurrent Pulmonary Metastases: A Case Report","volume":"48","author":"Takahashi","year":"2023","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1631\/jzus.B2000797","article-title":"LG-ESSs and HG-ESSs: Underlying Molecular Alterations and Potential Therapeutic Strategies","volume":"22","author":"Li","year":"2021","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kim, Y., Kim, D., Sung, W.J., and Hong, J. (2022). High-Grade Endometrial Stromal Sarcoma: Molecular Alterations and Potential Immunotherapeutic Strategies. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.837004"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ejogrb.2023.06.016","article-title":"Uterine Sarcomas: A Critical Review of the Literature","volume":"287","author":"Giannini","year":"2023","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s11864-024-01214-3","article-title":"Current Treatment Options: Uterine Sarcoma","volume":"25","author":"Lewis","year":"2024","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4143\/crt.2024.343","article-title":"Integrated Transcriptomic Landscape and Deep Learning Based Survival Prediction in Uterine Sarcomas","volume":"57","author":"Song","year":"2024","journal-title":"Cancer Res. Treat."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1177\/1933719118778801","article-title":"Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma","volume":"26","author":"Deshmukh","year":"2019","journal-title":"Reprod. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s13256-021-02838-x","article-title":"Complete Remission of Advanced Low\u2014Grade Endometrial Stromal Sarcoma after Aromatase Inhibitor Therapy: A Case Report","volume":"15","author":"Med","year":"2021","journal-title":"J. Med. Case Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e248971","DOI":"10.1136\/bcr-2022-248971","article-title":"Maintenance Therapy for Long-Term Control of High-Grade Endometrial Stromal Sarcoma","volume":"15","author":"Nakanishi","year":"2022","journal-title":"BMJ Case Rep."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Huang, X., and Peng, P. (2022). Hormone Therapy Reduces Recurrence in Stage II-IV Uterine Low-Grade Endometrial Stromal Sarcomas: A Retrospective Cohort Study . Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.922757"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100980","DOI":"10.1016\/j.gore.2022.100980","article-title":"Evaluating the Role of Aromatase Inhibitors in the Treatment of Low-Grade Endometrial Stromal Sarcomas","volume":"40","author":"Crowley","year":"2022","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"106","DOI":"10.21037\/atm-22-6463","article-title":"Efficacy and Safety of Apatinib in Patients with Recurrent Uterine Malignancy: A Prospective, Single-Center, Single-Arm, Phase 2 Study","volume":"11","author":"Ren","year":"2023","journal-title":"Ann. Transl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Yao, X., He, Y., Xiao, C., Zhou, R., Zhao, C., and Wang, W. (2024). The Potential of Immunotherapy for SMARCA4-Deficient Undifferentiated Uterine Sarcoma (SDUS). Biomolecules, 14.","DOI":"10.3390\/biom14080987"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Li, N., Yan, Y., Li, Y., Yang, Y., Dai, C., and Li, N. (2024). ATM, BLM, and CDH1 Gene Co-Mutations in a High-Grade Endometrial Stromal Sarcoma Patient with Multiple Abdominal Cavity Metastases: A Case Report and Literature Review. BMC Geriatr., 24.","DOI":"10.1186\/s12877-024-05201-z"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000535747","article-title":"Trabectedin and Radiotherapy in Endometrial Stromal Sarcoma: A Case Report","volume":"17","author":"Pedroza","year":"2024","journal-title":"Case Rep. Oncol."},{"key":"ref_30","first-page":"2","article-title":"Poor Prognosis in Low-Grade Endometrial Stromal Sarcoma With Cyclin-Dependent Kinase Inhibitor 2A Homozygous Deletion: A Case Study","volume":"16","author":"Mori","year":"2024","journal-title":"Cureus"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/PGP.0000000000000911","article-title":"Data Set for Reporting of Uterine Malignant and Potentially Malignant Mesenchymal Tumors: Recommendations From the International Collaboration on Cancer Reporting (ICCR)","volume":"41","author":"Nucci","year":"2022","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2632010X20916736","DOI":"10.1177\/2632010X20916736","article-title":"Immunohistochemical and Molecular Characterization of Endometrial Stromal Sarcomas","volume":"13","author":"Subbaraya","year":"2020","journal-title":"Clin. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1136\/ijgc-2024-005823","article-title":"ESGO\/EURACAN\/GCIG Guidelines for the Management of Patients with Uterine Sarcomas","volume":"34","author":"Casali","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/PAS.0000000000001215","article-title":"Undifferentiated Uterine Sarcomas Represent Underrecognized High-Grade Endometrial Stromal Sarcomas","volume":"43","author":"Cotzia","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Brahmi, M., Franceschi, T., Treilleux, I., Pissaloux, D., Ray-Coquard, I., Dufresne, A., Vanacker, H., Carbonnaux, M., Meeus, P., and Sunyach, M.P. (2020). Molecular Classification of Endometrial Stromal Sarcomas Using RNA Sequencing Defines Nosological and Prognostic Subgroups with Different Natural History. Cancers, 12.","DOI":"10.3390\/cancers12092604"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"101672","DOI":"10.1016\/j.gore.2024.101672","article-title":"BCOR Abnormalities in Endometrial Stromal Sarcoma","volume":"57","author":"Fayoumi","year":"2025","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/PAI.0000000000001213","article-title":"Diagnostic Value of Combined BCOR, Cyclin D1, and CD10 in Differentiating Endometrial Stromal Sarcoma From Other Uterine Spindle Cell Lesions","volume":"32","author":"Abouelkhair","year":"2024","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1111\/jog.14436","article-title":"Endometrial Stromal Sarcoma: A Review of Rare Mesenchymal Uterine Neoplasm","volume":"46","author":"Capozzi","year":"2020","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13000-023-01347-3","article-title":"Pathological Characteristics and Immune Microenvironment of SMARCA4-Deficient Undifferentiated Uterine Sarcoma","volume":"18","author":"Gao","year":"2023","journal-title":"Diagn. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Maccaroni, E., Lunerti, V., Agostinelli, V., Giampieri, R., Zepponi, L., Pagliacci, A., and Berardi, R. (2022). New Insights into Hormonal Therapies in Uterine Sarcomas. Cancers, 14.","DOI":"10.3390\/cancers14040921"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00404-019-05308-4","article-title":"The Clinical Benefits of Hormonal Treatment for LG\u2014ESS: A Meta\u2014Analysis","volume":"300","author":"Cui","year":"2019","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/s41379-020-00705-6","article-title":"Targeted RNA Expression Profiling Identifies High-Grade Endometrial Stromal Sarcoma as a Clinically Relevant Molecular Subtype of Uterine Sarcoma","volume":"34","author":"Mohammad","year":"2021","journal-title":"Mod. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/his.14608","article-title":"JAZF1, YWHAE and BCOR Gene Translocation in Primary Extrauterine Low-Grade and High-Grade Endometrial Stromal Sarcomas","volume":"80","author":"Sun","year":"2022","journal-title":"Histopathology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"110889","DOI":"10.1016\/j.celrep.2022.110889","article-title":"JAZF1-SUZ12 Dysregulates PRC2 Function and Gene Expression during Cell Differentiation","volume":"39","author":"Tavares","year":"2022","journal-title":"Cell Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1200\/EDBK_350541","article-title":"Novel Therapeutics in the Treatment of Uterine Sarcoma","volume":"42","author":"Bose","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. B"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/ijc.33811","article-title":"Wnt Pathway Modulators in Cancer Therapeutics: An Update on Completed and Ongoing Clinical Trials","volume":"150","author":"Neiheisel","year":"2022","journal-title":"Int. J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/s41379-021-01003-5","article-title":"ESR1 Hotspot Mutations in Endometrial Stromal Sarcoma with High-Grade Transformation and Endocrine Treatment","volume":"35","author":"Dessources","year":"2022","journal-title":"Mod. Pathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13058-021-01462-3","article-title":"ESR1 Mutation as an Emerging Clinical Biomarker in Metastatic Hormone Receptor-Positive Breast Cancer","volume":"23","author":"Brett","year":"2021","journal-title":"Breast Cancer Res."},{"key":"ref_49","first-page":"e35748","article-title":"Retrospective Evaluation of Fulvestrant Efficacy and Clinical Results in Patients Using Fulvestrant","volume":"15","author":"Kut","year":"2023","journal-title":"Cureus"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Andrahennadi, S., Sami, A., Haider, K., Chalchal, H.I., Le, D., Ahmed, O., Manna, M., El-Gayed, A., Wright, P., and Ahmed, S. (2021). Efficacy of Fulvestrant in Women with Hormone-Resistant Metastatic Breast Cancer (MBC): A Canadian Province Experience. Cancers, 13.","DOI":"10.21203\/rs.3.rs-538054\/v1"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"100044","DOI":"10.1016\/j.modpat.2022.100044","article-title":"High-Grade Endometrial Stromal Sarcomas With YWHAE::NUTM2 Gene Fusion Exhibit Recurrent CDKN2A Alterations and Absence of P16 Staining Is a Poor Prognostic Marker","volume":"36","author":"Kommoss","year":"2023","journal-title":"Mod. Pathol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1038\/s41379-021-00873-z","article-title":"Clinicopathological and Genomic Characterization of BCORL1 -Driven High-Grade Endometrial Stromal Sarcomas","volume":"34","author":"Lin","year":"2021","journal-title":"Mod. Pathol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41389-021-00327-w","article-title":"YWHAE-NUTM2 Oncoprotein Regulates Proliferation and Cyclin D1 via RAF\/MAPK and Hippo Pathways","volume":"10","author":"Ou","year":"2021","journal-title":"Oncogenesis"},{"key":"ref_54","first-page":"e2100211","article-title":"Clinical Utility of CDK4\/6 Inhibitors in Sarcoma: Successes and Future Challenges Abstract","volume":"6","author":"Hsu","year":"2022","journal-title":"Target. Drug Ther."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Ortega, \u00c1., Vera, I., Diaz, M.P., Navarro, C., Rojas, M., Torres, W., Parra, H., Salazar, J., De Sanctis, J.B., and Berm\u00fadez, V. (2022). The Yap\/Taz Signaling Pathway in the Tumor Microenvironment and Carcinogenesis: Current Knowledge and Therapeutic Promises. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010430"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00428-024-03908-3","article-title":"ERBB2\/ERBB3-Mutated S100\/SOX10-Positive Unclassified High-Grade Uterine Sarcoma: First Detailed Description of a Novel Entity","volume":"485","author":"Agaimy","year":"2024","journal-title":"Virchows Arch."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"978","DOI":"10.4143\/crt.2022.1647","article-title":"Genomic and Transcriptomic Characterization Revealed the High Sensitivity of Targeted Therapy and Immunotherapy in a Subset of Endometrial Stromal Sarcoma","volume":"55","author":"Kang","year":"2023","journal-title":"Cancer Res. Treat."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Kim, Y., Aiob, A., Kim, H., Suh, D.H., Kim, K., Kim, Y.B., and No, J.H. (2023). Clinical Implication of PD-L1 Expression in Patients with Endometrial Cancer. Biomedicines, 11.","DOI":"10.3390\/biomedicines11102691"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13000-022-01251-2","article-title":"Expression of Immune Checkpoint Regulators, Programmed Death-Ligand 1 (PD-L1\/PD-1), Cytotoxic T Lymphocyte Antigen 4 (CTLA-4), and Indolaimine-2, 3-Deoxygenase (IDO) in Uterine Mesenchymal Tumors","volume":"17","author":"Samiei","year":"2022","journal-title":"Diagn. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Peng, L., Li, J., Wu, J., Xu, B., Wang, Z., and Giamas, G. (2021). A Pan-Cancer Analysis of SMARCA4 Alterations in Human Cancers. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.762598"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Tuyaerts, S., and Amant, F. (2018). Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy. Vaccines, 6.","DOI":"10.3390\/vaccines6030056"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"37","DOI":"10.21037\/gpm-20-77","article-title":"Chemotherapy and Uterine Sarcomas: A Narrative Review","volume":"4","author":"Ferrero","year":"2021","journal-title":"Gynecol. Pelvic Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"132","DOI":"10.29328\/journal.cjog.1001141","article-title":"High-Grade Endometrial Mesenchymal Sarcoma: Current Status and Future Trends","volume":"6","author":"Zhang","year":"2023","journal-title":"Clin. J. Obstet. Gynecol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00280-021-04291-5","article-title":"Autophagy Inhibitor Potentiates the Antitumor Efficacy of Apatinib in Uterine Sarcoma by Stimulating PI3K\/Akt\/MTOR Pathway","volume":"88","author":"Chen","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"101044","DOI":"10.1016\/j.gore.2022.101044","article-title":"Gynecologic Oncology Reports Clinical Use of PARP Inhibitor in Recurrent Uterine Leiomyosarcoma with Presence of a Somatic BRCA2 Mutation","volume":"42","author":"Shammas","year":"2022","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/oncolo\/oyae082","article-title":"Clinical Actionability of BRCA2 Alterations in Uterine Leiomyosarcoma: A Molecular Tumor Board Case Report and a CBioPortal Comprehensive Analysis","volume":"29","author":"Bielo","year":"2024","journal-title":"Oncologist"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13046-023-02687-0","article-title":"Targeting Homologous Recombination Deficiency in Uterine Leiomyosarcoma","volume":"42","author":"Dall","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/his.14292","article-title":"P53 Immunohistochemical Analysis of Fusion-Positive Uterine Sarcomas","volume":"78","author":"Mohammad","year":"2021","journal-title":"Histopathology"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/2\/265\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:31:36Z","timestamp":1760027496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/2\/265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":68,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["biom15020265"],"URL":"https:\/\/doi.org\/10.3390\/biom15020265","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]}}}